Middle East & Africa Gastrointestinal Drugs Market Growth and Recent Trends by 2027

The Middle East & Africa gastrointestinal drugs market is expected to reach US$ 2,573.94 million by 2027 from US$ 2,000.27 million in 2019; it is estimated to grow at a CAGR of 3.3 % from 2020 to 2027.

Rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the key factors driving the growth of gastrointestinal drugs. However, side effects associated with the drugs is the major factor hindering the market growth in Asia Pacific.

Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhoea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the Middle East & Africa Gastrointestinal Drugs market in the forecast period.

Gastrointestinal diseases are becoming prevalent. Rapidly progressing research activities in drug development of novel therapeutics are driving the growth of the market. Many research institutes are offering funding to accelerate the discovery of novel methods for the treatment of GI disorders, which is offering lucrative opportunities for the discovery of new therapies. The major research areas are understanding mechanisms responsible for pancreatic inflammation and pancreatitis genetics and immunobiology of inflammatory bowel disease.

Moreover, the pharmaceutical industry is continually evolving. There is always a need for new, innovative therapeutic approaches in the treatment of various GI indications. The GI candidates-based pipeline is growing for a wide range of therapeutic applications, including Crohn's disease, Ulcerative colitis, inflammatory bowel disease, and others. Many big and small pharmaceutical companies are engaged in the development of several GI biologics drugs. Thus, the growing innovative pipeline of GI drugs is, in turn, boosting the drug discovery activities across the industry.

Middle East countries have registered a growth in the number of COVID cases in the last few days, with the UAE registering 85,595 cases, Saudi Arabia reporting 336,766, and South Africa indicating 682,215 confirmed cases. However, gastrointestinal drug market in this pandemic is on rising, due to the increasing awareness about treatments of gastrointestinal disorders in the region.

Rest of Middle East & Africa Gastrointestinal drugs Market, Revenue and Forecast to 2027 (US$ Mn)

MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SEGMENTATION

By Drug Class

• Acid Neutralizers
• Antidiarrheal and Laxatives
• Anti-Inflammatory Drugs
• Antiemetic and Antinauseants
• Biologics
• Others

By Route of Administration

• Oral
• Parenteral

By Application

• Inflammatory Ulcerative Colitis
• Crohn's Disease
• Irritable Bowel Syndrome
• Gastroenteritis
• Celiac Disease
• Others

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Country

• Saudi Arabia
• UAE
• South Africa
• Rest of Middle East and Africa

Company Profiles

• Johnson and Johnson Services, Inc.
• GlaxoSmithKline plc
• Celltrion Healthcare Co.,Ltd.
• AstraZeneca
• Takeda Pharmaceutical Company Limited

Middle East & Africa Gastrointestinal Drugs Report Scope